Juno Therapeutics (JUNO) Tops Q3 EPS by 6c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/12/2026
Go back to Juno Therapeutics (JUNO) Tops Q3 EPS by 6c
November 3, 2017 6:02 AM EDT
Cowen raised its price target on Juno Therapeutics (NASDAQ: JUNO) to $60.00 (from $49.00) while maintaining an Outperform rating.
Analyst Chris Shibutani believes robust efficacy, safety and durability data for JCAR017 in DLBCL from more patients at ASH can further bolster confidence in Junos competitive... More
November 2, 2017 6:48 AM EDT
(Updated - November 2, 2017 7:52 AM EDT)
(updated to expand analyst comment)
SunTrust Robinson Humphrey upgraded Juno Therapeutics (NASDAQ: JUNO) from Hold to Buy with a price target of $65.00 (from $25.00).
Analyst Peter Lawson likes the company's best-in-class safety and efficacy... More
November 2, 2017 6:43 AM EDT
Wedbush analyst David Nierengarten raised his price target on Juno Therapeutics (NASDAQ: JUNO) to $64.00 (from $42.00) while maintaining an Outperform rating after the ASH update shows 6mo response rates with JCAR017 in TRANSCEND at high dose are superior to that achieved with competing CAR-Ts (comparing... More
